Wisconsin Legislature: CSB 2.009 Note

CSB 2.009 NoteCSB 2.67 Addition of Brexanolone and Solriamfetol to schedule IV. Section 961.20 (2) (ap) and (2m) (g), Stats., are created to read:

CSB 2.009 Note961.20 (2) (ap) Brexanolone;

CSB 2.009 Note(2m) (g) Solriamfetol.

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2019 No. 763, eff. 7-22-19; CR 20-049: cr. Register June 2021 No. 786, eff. 7-1-21; correction in (2) (ap) made under s. 35.17, Stats., Register June 2021 No. 785.

CSB 2.009 NoteCSB 2.68 Addition of N-Ethylhexedrone, a-PHP, 4-MEAP, MPHP, PV8 and 4-chloro-a-PVP to schedule I. Section 961.14 (7) (L) 35. to 40., Stats., is created to read:

CSB 2.009 Note961.14 (7) (L) 35. N-Ethylhexedrone.

CSB 2.009 Note36. Alpha-pyrrolidinohexanophenone, commonly known as a-PHP.

CSB 2.009 Note37. 4-methyl-alpha-ethylainopentiophenone, commonly known as 4-MEAP.

CSB 2.009 Note38. 4’-methyl-alpha-pyrrolidinohexiophenone, commonly known as MPHP.

CSB 2.009 Note39. Alpha-pyrrolidinoheptaphenone, commonly known as PV8.

CSB 2.009 Note40. 4’-chloro-alpha-pyrrolidinovalerophenone, commonly known as 4-chloro-a-PVP.

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4g), Stats., Register August 2019 No. 764, eff. 8-19-19; CR 20-050: cr. Register June 2021 No. 786, eff. 7-1-21.

CSB 2.009 NoteCSB 2.69 Addition of Noroxymorphone to schedule II. Section 961.16 (2) (a) 10m., Stats., is created to read:

CSB 2.009 Note961.16 (2) (a) 10m. Noroxymorphone.

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2019 No. 767, eff. 11-11-19; CR 20-051: cr. Register June 2021 No. 786, eff. 7-1-21.

CSB 2.009 NoteCSB 2.70 Scheduling 4F-MDMB-BINACA and MMB-FUBICA. Section 961.14 (4) (tb) 38m. and 43m., Stats., are created to read:

CSB 2.009 Note961.14 (4) (tb) 38m. Methyl 2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate, commonly known as 4F-MDMB-BINACA or 4F-MDMB-BUTINACA.

CSB 2.009 Note43m. Methyl 2-(1-(4-fluorobenzyl)-1H-indole-3-carboxamido)-3-methylbutanoate, commonly known as MMB-FUBICA or AMB-FUBICA.

CSB 2.009 HistoryHistory: EmR2017: emerg. cr., eff. 6-26-20; CR 20-022: cr. Register May 2021 No. 785, eff. 6-1-21.

CSB 2.009 NoteCSB 2.71 Addition of lasmiditan to schedule V. Section 961.22 (8), Stats., is created to read:

CSB 2.009 Note961.22 (8). Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2-yl-benzamide].

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 3-23-20; CR 20-058: cr. Register July 2021 No. 787, eff. 8-1-21.

CSB 2.009 NoteCSB 2.72 Scheduling of isotonitazene and 1P-LSD. Section 961.14 (2) (pe) and (4) (jm), Stats., are created to read:

CSB 2.009 Note961.14 (2) (pe) Isotonitazene;

CSB 2.009 Note961.14 (4) (jm) 1-propionyl-lysergic acid diethylamide, commonly known as 1P-LSD;

CSB 2.009 HistoryHistory: EmR2013: emerg. cr., eff. 6-5-20; CR 20-023: cr. Register May 2021 No. 785, eff. 6-1-21; correction made under s. 35.17, Stats., Register May 2021 No. 785.

CSB 2.009 NoteCSB 2.73 Addition of cenobamate to schedule V. Section 961.22 (9), Stats., is created to read:

CSB 2.009 Note961.22 (9) CENOBAMATE Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate; 2H-tetrazole-2-ethanol, alpha-(2-chlorophenyl)-, carbamate (ester), (alphaR)-; carbamic acid (R)-(+)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethyl ester)

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2020 No. 773, eff. 5-18-20; CR 20-075: cr. Register July 2021 No. 787, eff. 8-1-21.

CSB 2.009 NoteCSB 2.74 Addition of Lemborexant to schedule IV. Section 961.20 (2) (eqm), Stats., is created to read:

CSB 2.009 Note961.20 (2) (eqm) Lemborexant.

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register March 2020 No.771, eff. 5-18-20; CR 20-076: cr. Register July 2021 No. 787, eff. 8-1-21; correction made under s. 35.17, Stats., Register July 2021 No. 787.

CSB 2.009 NoteCSB 2.75 Exclusion of approved cannabidiol drugs from schedule I. (1) Section 961.14 (4) (t) 4., Stats., is created to read:

CSB 2.009 Note961.14 (4) (t) 4. A drug product in finished dosage formulation that has been approved by the United States food and drug administration that contains cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.

CSB 2.009 Note(2) Section 961.22 (7) is repealed.

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4g), Stats., Register June 2020 No. 774, eff. 6-29-20; CR 20-077: cr. Register July 2021 No. 787, eff. 8-1-21.

CSB 2.009 NoteCSB 2.76 Addition of norfentanyl to schedule II. (1) Section 961.16 (8) (b), Stats., is renumbered 961.16 (8) (b) (intro.) and amended to read:

CSB 2.009 Note961.16 (8) (b) An immediate precursor to fentanyl, including all of the following:

CSB 2.009 Note1. 4-anilino-N-phenethyl-4-piperidine, commonly known as ANPP.

CSB 2.009 Note(2) Section 961.16 (8) (b) 2., Stats. is created to read:

CSB 2.009 Note2. N-phenyl-N-(piperidin-4-yl)propionamide, commonly known as norfentanyl.

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register June 2020 No. 774, eff. 6-29-20; CR 20-078: cr. Register July 2021 No. 787, eff. 8-1-21.

CSB 2.009 NoteCSB 2.77 Scheduling of flualprazolam. Section 961.20 (2) (ef), Stats., is created to read:

CSB 2.009 Note961.20 (2) (ef) Flualprazolam;

CSB 2.009 HistoryHistory: EmR1037: emerg. cr., eff. 10-27-20; CR 20-078: cr. Register July 2021 No. 787, eff. 8-1-21; correction made under s. 35.17, Stats., Register July 2021 No. 787.

CSB 2.009 NoteCSB 2.78 Addition of crotonyl fentanyl to schedule I. Section 961.14 (2) (nd) 9m., Stats., is created to read:

CSB 2.009 Note961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2- enamide);

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2020 No. 779, eff. 11-23-20; CR 22-011: cr. Register June 2023 No. 810, eff. 7-1-23; correction made under s. 35.17, Stats., Register June 2023 No. 810.

CSB 2.009 NoteCSB 2.79 Addition of remimazolam to schedule IV. Section 961.20 (2) (mo), Stats., is created to read:

CSB 2.009 Note961.20 (2) (mo) Remimazolam;

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register November 2020 No. 779, eff. 11-23-20; CR 22-014: cr. Register June 2023 No. 810, eff. 7-1-23; correction made under s. 35.17, Stats., Register June 2023 No. 810.

CSB 2.009 NoteCSB 2.80 Scheduling of oliceridine. Section 961.16 (3) (ta), Stats., is created to read:

CSB 2.009 Note961.16 (3) (ta) Oliceridine;

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register December 2020 No. 780, eff. 12-14-20; CR 21-098: cr. Register August 2022 No. 800, eff. 9-1-22.

CSB 2.009 NoteCSB 2.81 Addition of brorphine to schedule I. Section 961.14 (2) (et), Stats., is created to read:

CSB 2.009 Note961.14 (2) (et) Brorphine;

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register May 2021 No. 785, eff. 4-26-21; correction made under s. 35.17, Stats., Register May 2021 No. 785; CR 22-016: cr. Register June 2023 No. 810, eff. 7-1-23; correction made under s. 35.17, Stats., Register June 2023 No. 810.

CSB 2.009 NoteCSB 2.82 Addition of Serdexmethylphenidate to schedule IV. Section 961.20 (2m) (em), Stats., is created to read:

CSB 2.009 Note961.20 (2m) (em) Serdexmethylphenidate.

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7-12-21; CR 22-032: cr. Register June 2023 No. 810, eff. 7-1-23.

CSB 2.009 NoteCSB 2.83 Addition of ten (10) fentanyl-related substances to schedule I. Section 961.14 (2) (nd) 21., 22., 23., 24., 25., 26., 27., 28., 29., and 30., Stats., is created to read:

CSB 2.009 Note961.14 (2) (nd) 21. N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide (2’-fluoro ortho-fluorofentanyl; 2’-fluoro 2-fluorofentanyl);

CSB 2.009 Note22. N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide (4’-methyl acetyl fentanyl);

CSB 2.009 Note23. N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide (b’-phenyl fentanyl; beta’-Phenyl fentanyl; 3-phenylpropanoyl fentanyl);

CSB 2.009 Note24. N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide (b-methyl fentanyl);

CSB 2.009 Note25. N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide (ortho-fluorobutyryl fentanyl; 2-fluorobutyryl fentanyl);

CSB 2.009 Note26. N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl acetylfentanyl; 2-methyl acetylfentanyl);

CSB 2.009 Note27. 2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide (ortho-methyl methoxyacetylfentanyl; 2-methyl methoxyacetyl fentanyl);

CSB 2.009 Note28. N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide (para-methylfentanyl; 4-methylfentanyl);

CSB 2.009 Note29. N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide (phenyl fentanyl; benzoyl fentanyl);

CSB 2.009 Note30. N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide (thiofuranyl fentanyl; 2-thiofuranyl fentanyl; thiophene fentanyl).

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7-19-21; correction made under s. 35.17, Stats., Register July 2021 No. 787; CR 22-033: cr. Register June 2023 No. 810, eff. 7-1-23.

CSB 2.009 NoteCSB 2.84 Addition of alfaxalone to schedule IV. (1) Section 961.20 (2) (a), Stat., is repealed and recreated to read:

CSB 2.009 Note961.20 (2) (a) Alfaxalone;

CSB 2.009 Note(2) Section 961.20 (2) (ak) is created to read:

CSB 2.009 Note961.20 (2) (ak) Alprazolam;

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7-19-21; correction in numbering made under s. 13.92 (4) (b) 1, Stats., and correction made under s. 35.17, Stats., Register July 2021 No. 787; CR 22-034: cr. Register June 2023 No. 810, eff. 7-1-23; correction in numbering made under s. 13.92 (4) (b) 1, Stats., and correction made under s. 35.17, Stats., Register June 2023 No. 810.

CSB 2.009 NoteCSB 2.85 Excluding 6-beta-naltrexol from schedule II. Section 961.16 (2) (a), Stats., is amended to read:

CSB 2.009 Note961.16 (2) (a) Opium and substances derived from opium, and any salt, compound, derivative or preparation of opium or substances derived from opium. Apomorphine, dextrorphan, nalbuphine, butorphanol, naldemedine, nalmefene, naloxegol, naloxone, 6-beta-naltrexol, and naltrexone and their respective salts and the isoquinoline alkaloids of opium and their respective salts are excluded from this paragraph. The following substances, and any of their salts, isomers and salts of isomers that are theoretically possible within the specific chemical designation, are included in this paragraph:

CSB 2.009 NoteCSB 2.86 Addition of fospropofol to schedule IV. Section 961.20 (2) (en), Stats., is created to read:

CSB 2.009 Note961.20 (2) (en) Fospropofol;

CSB 2.009 NoteCSB 2.87 Addition of embutramide to schedule III. Section 961.18 (3) (bm), Stats., is created to read:

CSB 2.009 Note961.18 (3) (bm) Embutramide;

CSB 2.009 NoteCSB 2.88 Addition of lacosamide to schedule V. Section 961.22 (10), Stats., is created to read:

CSB 2.009 Note961.22 (10) Lacosamide.

CSB 2.009 HistoryHistory: cr. Affirmative action order under s. 961.11 (4), Stats., Register July 2021 No. 787, eff. 7-19-21; CR 22-039: cr. Register June 2023 No. 810, eff. 7-1-23.